Home > Healthcare > Medical Devices > Diagnostic Devices > Theranostics Market

Theranostics Market Size

  • Report ID: GMI8468
  • Published Date: Mar 2024
  • Report Format: PDF

Theranostics Market Size

Theranostics Market was valued at USD 2.2 billion in 2023 and is estimated to grow at a CAGR of 13.6% between 2024 and 2032. Theranostics is a term that combines "therapy" and "diagnostics" and refers to an approach in medicine where diagnostic tests and therapeutic interventions are integrated into a single platform. This concept aims to personalize and optimize patient care by tailoring treatments based on individual characteristics, such as disease biology, genetic makeup, and treatment response. Diagnostic techniques are used to identify specific biomarkers, molecular targets, or disease characteristics, which inform the selection of appropriate therapies. These therapies can include targeted drugs, immunotherapies, or radiation therapies, often delivered with precision to maximize efficacy and minimize side effects.

 

The increasing prevalence of targeted diseases such cancer, cardiovascular diseases, autoimmune diseases has emerged as a significant driver for the market. For instance, according to the World Health Organization (WHO), in 2020, cancer accounted for nearly 10 million deaths worldwide. Therefore, there is a rising need for innovative theranostic approaches that integrate diagnostics and therapies to personalize treatment strategies, optimize patient care, and improve outcomes for individuals affected by these diseases.
 

Furthermore, growing technological advancements in the field, an increasing focus on precision medicine, and the rising geriatric population, among other contributing factors propelling the growth of the market in the forthcoming years.
 

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Market size for theranostics was USD 2.2 billion in 2023 and is expected to register 13.6% CAGR from 2024-2032 owing to the increasing prevalence of targeted diseases such cancer, cardiovascular diseases, and autoimmune diseases worldwide.

Theranostics industry from the diagnostic imaging segment reached USD 743 million in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to its ability to detect diseases at early stages when treatment is most effective.

North America industry for theranostics recorded USD 877.3 million in 2023 and is expected to register a commendable CAGR from 2024- 2032 due to the presence of advanced technological landscapes that foster the development of innovative theranostics in the region.

Canon Medical Systems Corporation, Curium, F. Hoffmann La Roche Ltd., GE HealthCare Technologies Inc., Koninklijke Philips N.V., Lantheus Holdings, Inc., Siemens Healthnieers AG , and Thermo Fisher Scientific Inc., are some of the major theranostics companies worldwide.

Theranostics Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 11
  • Tables & Figures: 253
  • Countries covered: 22
  • Pages: 192
 Download Free Sample